Clinical Study

Hypertension Control and Cardiometabolic Risk: A Regional Perspective

Table 1

Patient characteristics.

Total
( )
Northern Europe
( )
Southern Europe
( )
North America
( )
Middle East
( )
Asia
( )

Age63.164.962.565.757.160.5
Gender (male, %)52.853.052.956.361.048.5
BMI (kg/m²)28.929.729.230.229.825.9
Waist circumference (cm)99.7102.5100.9102.6102.589.5
Systolic blood pressure (mmHg)148.9151.5148.6144.3156.6145.1
Diastolic blood pressure (mmHg)87.087.787.781.492.085.6
Uncontrolled blood pressure (%)*76.382.175.664.987.969.5
Diabetes mellitus (%)29.133.927.430.933.821.7
HbA1c (%)6.86.76.76.77.97.1
LDL cholesterol (mmol/L)3.23.23.32.63.43.1
HDL cholesterol (mmol/L)1.31.51.31.31.11.3
Triglycerides (mmol/L)1.81.91.71.72.01.8
Hyperlipidemia (%)49.053.043.364.456.146.1
Smoking (current/past; %)38.836.441.855.744.928.5
Family history of MI (%)28.622.029.640.025.536.3
Microalbuminuria (%)58.654.359.653.871.664.7
CRP (mg/dL)0.921.020.910.540.910.49
Coronary artery disease (%)25.121.523.740.530.426.4
Congestive heart failure (%)6.46.36.75.58.36.0
Atrial fibrillation (%)9.39.511.111.74.74.0
Myocardial infarction (%)31.624.434.141.727.937.1
Ischemic stroke (%)5.124.75.55.64.414.6
Peripheral artery disease (%)4.66.15.05.74.70.5
Betablockers (%)48.759.740.244.852.548.1
Calcium Antagonists (%)36.030.331.943.436.753.6
ACE-Inhibitors (%)42.345.842.849.531.932.1
AT1-Rezeptorantagonists (%)35.830.141.331.147.934.4
Diuretics (%)9.910.910.58.010.77.4

*Uncontrolled blood pressure was defined as SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients.